Lupeol acetate |
| Catalog No.GC60231 |
L'acétate de lupéol, un dérivé du lupéol, supprime la progression de la polyarthrite rhumatoÏde (PR) en inhibant l'activation des macrophages et de l'ostéoclastogenèse par des régulations négatives du TNF-α, de l'IL-1β, du MCP-1, du COX-2, du VEGF et du granzyme B[1 ].
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1617-68-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Lupeol acetate, a derivative of Lupeol, suppresses the progression of rheumatoid arthritis (RA) by inhibiting the activation of macrophages and osteoclastogenesis through downregulations of TNF-α, IL-1β, MCP-1, COX-2, VEGF and granzyme B[1].
[1]. Wang WH, et al. Lupeol acetate ameliorates collagen-induced arthritis and osteoclastogenesis of mice through improvement of microenvironment. Biomed Pharmacother. 2016;79:231-240.
Average Rating: 5 (Based on Reviews and 15 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *